Press releases
- InDex Pharmaceuticals receives grant from Vinnova for pre-clinical development of DIMS compounds in inflammation31 March 2020 - Other press release
- InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 201930 March 2020 - Regulatory press release
- Notice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)19 March 2020 - Regulatory press release
Cobitolimod
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.
Learn moreCalender
- 20 April 2020Annual General Meeting
- 7 May 2020Interim report Q1
- 26 August 2020Interim report Q2
- 25 November 2020Interim report Q3
